IL6 and neoplasm: In this study, baseline IL‐6 was a better predictor of clinical response to αPD‐(L)1 inhibitors than tumour PD‐L1 expression, and also associated with OS in subgroup analyses of patients with no/low tumour PD‐L1 expression.